FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT...
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the publication of preclinical data on its stabilized immune modulatory...
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced that Robert Karr, M.D., President of Idera, will discuss the Company?s...
Idera Pharmaceuticals (AMEX: IDP) today reported financial results for the three and six months ended June 30, 2007. ?Our...
Idera Pharmaceuticals (AMEX: IDP) today announced the publication of preclinical data demonstrating that its Toll-like Receptor...
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the presentation of preclinical data using its proprietary antagonists of...
Idera Pharmaceuticals (AMEX: IDP) today announced that Robert Andersen, the Company?s Chief Financial Officer and Vice...
Idera Pharmaceuticals (AMEX: IDP) today announced financial results for the quarter ended March 31, 2007 and provided an outline...
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced its participation in two sessions at the 2007 BIO International...
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced two presentations of data for two new potential applications in oncology...
Idera Pharmaceuticals Inc. (AMEX: IDP), a biopharmaceutical company focused on developing therapeutics targeting Toll-like...
Idera Pharmaceuticals Inc. (AMEX: IDP), announced today that Novartis has decided to extend the term of the research phase of...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.